9/18/2020  5:30:53 PM Chg. +6.20 Volume Bid9:42:29 PM Ask6:40:00 PM Market Capitalization Dividend Y. P/E Ratio
343.10CHF +1.84% 4.51 mill.
Turnover: 1.25 bill.
341.70Bid Size: 132 343.00Ask Size: 5 295.64 bill.CHF 2.62% 21.76

Business description

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
 

Management board & Supervisory board

CEO
Dr. Severin Schwan
Management board
Cristina A. Wilbur, Dr. Alan Hippe, Thomas Schinecker, William Anderson
Supervisory board
Dr. Christoph Franz, André Hoffmann, Anita Hauser, Bernard Poussot, Dr. Claudia Süssmuth Dyckerhoff, Dr. Jo¨rg Duschmalé, Dr. Patrick Frost, Dr. Severin Schwan, Julie Brown, Paul Bulcke, Prof. Dr. Hans Clevers, Prof. Dr. Richard Lifton
 

Company data

Name: Roche Holding
Address: Grenzacherstraße 124,CH-4070 Basel
Phone: +41-61-688-1111
Fax: -
E-mail: basel.webmaster@roche.com
Internet: www.roche.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 16.60%
IPO date: -

Investor relations

Name: Karl Mahler
IR phone: +41-61-687-8503
IR Fax: -
IR e-mail: investor.relations@roche.com

Company calendar

CW 42 | 10/15/2020 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Aktionärsgruppe der Familien Hoffmann und Oeri-Hoffmann
 
45.01%
Novartis Ltd
 
33.33%
Freefloat
 
16.60%
Maja Oeri
 
5.06%
Others
 
0.00%